TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 36939601

Group type: EXPERIMENTAL
Intervention: Electronic memory and management aid (EMMA) tablet application
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Training usage of EMMA
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Teaching the aid to individuals with average-level language abilities
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Encouraging early and frequent use of the aid during training
Number of subjects: 32
Study: 36939629

Group type: EXPERIMENTAL
Intervention: Tesnatilimab 400 mg SC
Number of subjects: 388

Group type: COMPARATOR
Intervention: Placebo SC
Number of subjects: 388

Group type: EXPERIMENTAL
Intervention: Tesnatilimab 50 mg, 150 mg, 400 mg SC
Number of subjects: 388

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 388

Group type: EXPERIMENTAL
Intervention: Ustekinumab ~6 mg/kg IV at Week 0 and 90 mg SC at Weeks 8 and 16
Number of subjects: 388

Group type: EXPERIMENTAL
Intervention: Tesnatilimab
Number of subjects: 388
Study: 36939679

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioural-based intervention combined with mindfulness, psychoeducation, and relaxation techniques
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioural-based intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group with no intervention
Number of subjects: 0
Study: 36939728

Group type: EXPERIMENTAL
Intervention: Complex Care for Kids Ontario (CCKO) program
Number of subjects: 144

Group type: COMPARATOR
Intervention: Usual care (waitlist group)
Number of subjects: 144
Study: 36939774

Group type: EXPERIMENTAL
Intervention: Ibuprofen treatment
Number of subjects: 185
Study: 36939801

Group type: EXPERIMENTAL
Intervention: sEH inhibitors
Number of subjects: 500

Group type: COMPARATOR
Intervention: sEH activity
Number of subjects: 500
Study: 36939815

Group type: EXPERIMENTAL
Intervention: Inspiratory muscle training (IMT) combined with standard-of-care rehabilitation for 8 weeks
Number of subjects: 34

Group type: COMPARATOR
Intervention: Standard-of-care rehabilitation for 8 weeks
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: IMT using the POWERbreathe K5 IMT device
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Evaluation of dyspnea using Medical Research Council Scale and 18-point qualitative dyspnea descriptors
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Diaphragmatic thickening fraction using ultrasound
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Respiratory muscle endurance
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Pulmonary function
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Prefrontal cortical activity using functional near-infrared spectroscopy
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Aerobic capacity during cardiopulmonary exercise testing
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Quality of life using Short Form-36
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Scores from the Depression, Anxiety, and Stress scale-21
Number of subjects: 34
Study: 36939818

Group type: EXPERIMENTAL
Intervention: Telerehabilitation program
Number of subjects: 44

Group type: COMPARATOR
Intervention: Education and unstructured physical activity
Number of subjects: 44
Study: 36939832

Group type: EXPERIMENTAL
Intervention: Ivermectin MDA at 300 μg/kg for 3 consecutive days, provided under supervision to all eligible village inhabitants, over 2 successive rainy seasons.
Number of subjects: 14

Group type: COMPARATOR
Intervention: Standard measures (seasonal malaria chemoprevention [SMC] and bed net use for children aged 3 to 59 months) and placebo.
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Ivermectin MDA
Number of subjects: 14

Group type: COMPARATOR
Intervention: Standard measures and placebo
Number of subjects: 14
Study: 36939876

Group type: EXPERIMENTAL
Intervention: Early-stage breast cancer patients
Number of subjects: 30
Study: 36939879

Group type: EXPERIMENTAL
Intervention: Ultrasound measurement of diaphragmatic thickness (Tdi) at inspiration
Number of subjects: 137

Group type: EXPERIMENTAL
Intervention: Ultrasound measurement of diaphragmatic thickness (Tdi) at expiration
Number of subjects: 137

Group type: EXPERIMENTAL
Intervention: Ultrasound measurement of diaphragm thickening fraction (dTF)
Number of subjects: 137

Group type: EXPERIMENTAL
Intervention: Inter-rater reliability of ultrasound measurements
Number of subjects: 137
Study: 36939932

Group type: COMPARATOR
Intervention: Severe-critical group
Number of subjects: 428

Group type: EXPERIMENTAL
Intervention: Neurologic/Pain/Dermatologic component
Number of subjects: 428

Group type: EXPERIMENTAL
Intervention: Respiratory/Fever/Fatigue/Psychiatric component
Number of subjects: 428

Group type: EXPERIMENTAL
Intervention: Neurologic/Pain/Dermatologic and Respiratory/Fever/Fatigue/Psychiatric components
Number of subjects: 428

Group type: EXPERIMENTAL
Intervention: Initial symptoms
Number of subjects: 428
Study: 36939933

Group type: EXPERIMENTAL
Intervention: Atrial fibrillation (AF)
Number of subjects: 3285
Study: 36940069

Group type: EXPERIMENTAL
Intervention: Rivaroxaban (20 mg once daily or 15 mg if creatinine clearance was between 30 and 49 mL/min)
Number of subjects: 64
Study: 36940137

Group type: EXPERIMENTAL
Intervention: Grayson technique
Number of subjects: 30

Group type: COMPARATOR
Intervention: Figueroa technique
Number of subjects: 30
Study: 36940214

Group type: EXPERIMENTAL
Intervention: Physical-Psychological Integrative (PPI) intervention group
Number of subjects: 72

Group type: COMPARATOR
Intervention: Control group (didactic education program)
Number of subjects: 72
Study: 36940261

Group type: EXPERIMENTAL
Intervention: Atezolizumab plus PEGPH20 (n = 66)
Number of subjects: 79

Group type: COMPARATOR
Intervention: Chemotherapy (mFOLFOX6 or gemcitabine plus nab-paclitaxel) (n = 42)
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: Atezolizumab plus PEGPH20 (n = 13)
Number of subjects: 79

Group type: COMPARATOR
Intervention: Control (ramucirumab plus paclitaxel) (n = 12)
Number of subjects: 79
Study: 36940407

Group type: EXPERIMENTAL
Intervention: Isolated hepatic perfusion (IHP) with melphalan
Number of subjects: 93

Group type: COMPARATOR
Intervention: Best alternative care (Control)
Number of subjects: 93
Study: 36940437

Group type: EXPERIMENTAL
Intervention: 14-day hybrid therapy
Number of subjects: 918

Group type: COMPARATOR
Intervention: 14-day high-dose dual therapy
Number of subjects: 918

Group type: EXPERIMENTAL
Intervention: 10-day bismuth quadruple therapy
Number of subjects: 918
Study: 36940444

Group type: EXPERIMENTAL
Intervention: 2.5 mg of apixaban twice daily for 30 days
Number of subjects: 1217

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1217

Group type: EXPERIMENTAL
Intervention: 2.5 mg of apixaban
Number of subjects: 1217
Study: 36940739

Group type: EXPERIMENTAL
Intervention: BAP-EB attachment rate in women aged ≥35 years having a live birth
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: BAP-EB attachment rate
Number of subjects: 240
Study: 36940771

Group type: EXPERIMENTAL
Intervention: Intrapartum video education
Number of subjects: 161

Group type: COMPARATOR
Intervention: Standard of care (bedside coaching)
Number of subjects: 161
Study: 36940793

Group type: EXPERIMENTAL
Intervention: Advanced hybrid closed-loop (AHCL) system (Minimed 780G®)
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: AHCL system (Minimed 780G®)
Number of subjects: 46
Study: 36940951

Group type: EXPERIMENTAL
Intervention: Proton therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Photon therapy
Number of subjects: 0
Study: 36941030

Group type: EXPERIMENTAL
Intervention: High-flow (HF) oxygen therapy at flow rates of 2 L/kg for the first 10 kg, plus 0.5 L/kg for every kg >10 kg
Number of subjects: 107

Group type: COMPARATOR
Intervention: Low-flow (LF) oxygen therapy with a maximum flow rate of 3 L/min
Number of subjects: 107

Group type: COMPARATOR
Intervention: Low-flow (LF) oxygen therapy
Number of subjects: 107

Group type: EXPERIMENTAL
Intervention: High-flow (HF) oxygen therapy
Number of subjects: 107
Study: 36941099

Group type: EXPERIMENTAL
Intervention: Cord length: 2 cm
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: Cord length: 3 cm
Number of subjects: 99

Group type: COMPARATOR
Intervention: Control group (not measured)
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 99
Study: 36941133

Group type: EXPERIMENTAL
Intervention: 1,3-Beta-D-Glucan (BDG) concentration in peritoneal fluid
Number of subjects: 113

Group type: EXPERIMENTAL
Intervention: BDG threshold of 125 pg/mL
Number of subjects: 113

Group type: EXPERIMENTAL
Intervention: BDG concentrations in peritoneal fluid
Number of subjects: 113
Study: 36941155

Group type: EXPERIMENTAL
Intervention: M-001 (1.0-mg)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Saline placebo
Number of subjects: 120
Study: 36941402

Group type: EXPERIMENTAL
Intervention: Intravitreal aflibercept (IVT-AFL) treatment
Number of subjects: 0
Study: 36941575

Group type: EXPERIMENTAL
Intervention: ctDNA-guided chemotherapy
Number of subjects: 1621

Group type: COMPARATOR
Intervention: Standard of care chemotherapy
Number of subjects: 1621
Study: 36941621

Group type: EXPERIMENTAL
Intervention: Isocaloric ketogenic diet (ICKD) for 4 weeks
Number of subjects: 6

Group type: COMPARATOR
Intervention: Usual mixed Western-style diet (UD) for 4 weeks
Number of subjects: 6
Study: 36941656

Group type: EXPERIMENTAL
Intervention: HAT Sero-K-Set
Number of subjects: 2345

Group type: EXPERIMENTAL
Intervention: rHAT Sero-Strip
Number of subjects: 2345

Group type: EXPERIMENTAL
Intervention: SD Bioline HAT
Number of subjects: 2345

Group type: EXPERIMENTAL
Intervention: Presence of at least one clinical presentation (swollen lymph nodes, important weight loss, severe itching, motor disorders)
Number of subjects: 2345

Group type: EXPERIMENTAL
Intervention: Trypanolysis on DBS
Number of subjects: 2345

Group type: EXPERIMENTAL
Intervention: ELISA/T.b. gambiense on DBS
Number of subjects: 2345

Group type: EXPERIMENTAL
Intervention: LAMP and m18S qPCR
Number of subjects: 2345
Study: 36941683

Group type: EXPERIMENTAL
Intervention: Low tidal volume (VT) ventilation at low PEEP (5 cmH2O)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Low tidal volume (VT) ventilation at high PEEP
Number of subjects: 30

Group type: COMPARATOR
Intervention: Interrupted events due to high baseline ICP
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Lung protective ventilation (LPV)
Number of subjects: 30
Study: 36941714

Group type: EXPERIMENTAL
Intervention: Exhaustive drainage
Number of subjects: 304

Group type: COMPARATOR
Intervention: Fixed-time drainage
Number of subjects: 304
Study: 36942507

Group type: EXPERIMENTAL
Intervention: ASP1128 single dose (0.3-10 mg)
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: ASP1128 multiple dose (3-100 mg)
Number of subjects: 49

Group type: COMPARATOR
Intervention: Placebo (single dose)
Number of subjects: 49

Group type: COMPARATOR
Intervention: Placebo (multiple dose)
Number of subjects: 49
Study: 36942533

Group type: EXPERIMENTAL
Intervention: 4F-PCC (1 mL/kg, 25 IU of factor IX/kg)
Number of subjects: 324

Group type: COMPARATOR
Intervention: Placebo (1 mL/kg saline solution)
Number of subjects: 324

Group type: EXPERIMENTAL
Intervention: 4F-PCC
Number of subjects: 324

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 324
Study: 36942550

Group type: EXPERIMENTAL
Intervention: Therapeutic-dose heparin
Number of subjects: 3320

Group type: COMPARATOR
Intervention: Usual care pharmacologic thromboprophylaxis
Number of subjects: 3320
Study: 36942628

Group type: EXPERIMENTAL
Intervention: Convolution Neural Network (CNN) algorithm for diagnosing shockable rhythms
Number of subjects: 1005

Group type: EXPERIMENTAL
Intervention: Convolution Neural Network (CNN) algorithm for diagnosing nonshockable rhythms
Number of subjects: 1005

Group type: EXPERIMENTAL
Intervention: Convolution Neural Network (CNN) algorithm performance against noise artifacts
Number of subjects: 1005

Group type: COMPARATOR
Intervention: CNN algorithm compared to adjudicators for classifying atrial arrhythmias as nonshockable
Number of subjects: 1005
Study: 36942651

Group type: EXPERIMENTAL
Intervention: Sizanani trial participants
Number of subjects: 1143
Study: 36942721

Group type: EXPERIMENTAL
Intervention: Digital approach using intraoral scanner (IOS)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Analog approach using polyvinyl siloxane impression material
Number of subjects: 31
Study: 36942757

Group type: EXPERIMENTAL
Intervention: Collaterals originating from NIRA
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: Collaterals originating from IRA proximal to the acute STEMI occlusion
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: Collaterals originating from IRA distal to the acute occlusion
Number of subjects: 93
Study: 36942789

Group type: EXPERIMENTAL
Intervention: Intravenous hydrocortisone (200 mg daily for either 4 or 7 days, followed by tapering for a total of 8 or 14 days)
Number of subjects: 795

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 795

Group type: EXPERIMENTAL
Intervention: Intravenous hydrocortisone
Number of subjects: 795
Study: 36942937

Group type: EXPERIMENTAL
Intervention: Ixazomib, oral metronomic cyclophosphamide, and dexamethasone
Number of subjects: 12
Study: 36943075

Group type: EXPERIMENTAL
Intervention: LGE CMR analyzed by machine-learning algorithm
Number of subjects: 761

Group type: EXPERIMENTAL
Intervention: LGE CMR analyzed by humans
Number of subjects: 761

Group type: COMPARATOR
Intervention: Guideline criterion (LVEF of ≤35% and New York Heart Association class II or III)
Number of subjects: 761
Study: 36943168

Group type: EXPERIMENTAL
Intervention: Gaze-based phosphene mapping
Number of subjects: 3

Group type: COMPARATOR
Intervention: Finger-based phosphene mapping
Number of subjects: 3
Study: 36943214

Group type: EXPERIMENTAL
Intervention: Early postpartum IUD placement (2 to 4 weeks postpartum)
Number of subjects: 404

Group type: COMPARATOR
Intervention: Interval IUD placement (6 to 8 weeks postpartum)
Number of subjects: 404
Study: 36943254

Group type: EXPERIMENTAL
Intervention: Typhoid vaccine
Number of subjects: 156

Group type: COMPARATOR
Intervention: Saline placebo
Number of subjects: 156
Study: 36943309

Group type: EXPERIMENTAL
Intervention: Corneal Tissue Addition Keratoplasty (CTAK)
Number of subjects: 18
Study: 36943345

Group type: EXPERIMENTAL
Intervention: 6-month exercise training intervention
Number of subjects: 150

Group type: COMPARATOR
Intervention: 6-month stretching intervention (control)
Number of subjects: 150
Study: 36943360

Group type: EXPERIMENTAL
Intervention: Digital whiteboard (E-paper)
Number of subjects: 110
Study: 36943374

Group type: EXPERIMENTAL
Intervention: E-learning group
Number of subjects: 28

Group type: COMPARATOR
Intervention: Traditional group
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 28
Study: 36943405

Group type: EXPERIMENTAL
Intervention: Lumacaftor/Ivacaftor
Number of subjects: 0
Study: 36943437

Group type: EXPERIMENTAL
Intervention: Motor evoked potentials (MEPs) measured twice, 2 weeks apart, every 6 months.
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: TA latency and amplitude with facilitation
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Biceps latency with facilitation
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Longitudinal correlations of MEPs
Number of subjects: 10
Study: 36943669

Group type: EXPERIMENTAL
Intervention: High serum levels of monocyte/macrophage and endothelial activation markers, chemotaxis, and hematopoietic cytokines
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: High frequency of central memory CD4 T cells
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Gene expression profiles
Number of subjects: 0
Study: 36943907

Group type: EXPERIMENTAL
Intervention: Sacubitril/Valsartan
Number of subjects: 2031

Group type: COMPARATOR
Intervention: Enalapril
Number of subjects: 2031
Study: 36944059

Group type: EXPERIMENTAL
Intervention: Basal insulin Fc (BIF) once weekly
Number of subjects: 278

Group type: COMPARATOR
Intervention: Insulin Degludec once daily
Number of subjects: 278
Study: 36944116

Group type: EXPERIMENTAL
Intervention: Pegylated interferon alfa-2b (Peg-IFN)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 36944128

Group type: EXPERIMENTAL
Intervention: Ultrasound-Guided Transcutaneous Injection in the Lacrimal Gland
Number of subjects: 0
Study: 36944142

Group type: EXPERIMENTAL
Intervention: Drug/LA group (laser acupuncture therapy for 20 minutes per session, three sessions weekly, plus calcium and vitamin D 3 supplement containing fluoride)
Number of subjects: 68

Group type: COMPARATOR
Intervention: Drug-only group (calcium and vitamin D 3 supplement containing fluoride)
Number of subjects: 68
Study: 36944357

Group type: EXPERIMENTAL
Intervention: Atorvastatin 20 mg daily
Number of subjects: 587

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 587
Study: 36944461

Group type: EXPERIMENTAL
Intervention: Taurolidine-citrate-heparin lock solution
Number of subjects: 462

Group type: COMPARATOR
Intervention: Heparin-only lock solution
Number of subjects: 462
Study: 36944463

Group type: EXPERIMENTAL
Intervention: Single dose infusion of low-molecular weight iron dextran (1000 mg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo (normal saline)
Number of subjects: 0
Study: 36944485

Group type: COMPARATOR
Intervention: Non-intervention arm of the RCT (BabySMART)
Number of subjects: 106
Study: 36944559

Group type: EXPERIMENTAL
Intervention: bCTC count ≥3
Number of subjects: 589

Group type: EXPERIMENTAL
Intervention: bCTC count <3
Number of subjects: 589

Group type: COMPARATOR
Intervention: anti-VEGF treatment
Number of subjects: 589

Group type: COMPARATOR
Intervention: anti-EGFR treatment
Number of subjects: 589
Study: 36944583

Group type: EXPERIMENTAL
Intervention: NIFECG
Number of subjects: 285

Group type: COMPARATOR
Intervention: cCTG
Number of subjects: 285
Study: 36944694

Group type: EXPERIMENTAL
Intervention: General anesthesia with serratus anterior plane block (SAM) and pectoral nerve block type I (PECS I)
Number of subjects: 0

Group type: COMPARATOR
Intervention: General anesthesia alone
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: General anesthesia with SAM + PECS I
Number of subjects: 0
Study: 36944848

Group type: EXPERIMENTAL
Intervention: Trastuzumab (T)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Lapatinib (L)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Trastuzumab + Lapatinib (TL)
Number of subjects: 0
Study: 36944851

Group type: EXPERIMENTAL
Intervention: Virtually augmented self-hypnosis using virtual reality (VR) with the 'Aqua' module (Oncomfort™)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Virtually augmented self-hypnosis using virtual reality (VR)
Number of subjects: 100
Study: 36944930

Group type: EXPERIMENTAL
Intervention: Virtual reality (VR) intervention, 5-min duration via telehealth using a head-mounted immersive device.
Number of subjects: 120
Study: 36944929

Group type: EXPERIMENTAL
Intervention: Continuous cardiac rhythm monitoring with insertable cardiac monitor (Reveal LINQ, Medtronic) for atrial fibrillation (AF) detection
Number of subjects: 250
Study: 36944956

Group type: EXPERIMENTAL
Intervention: Lacticaseibacillus paracasei K56
Number of subjects: 74

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 74
Study: 36944986

Group type: COMPARATOR
Intervention: Center-based intervention group (CBI)
Number of subjects: 325

Group type: COMPARATOR
Intervention: Center-based plus home-based intervention group (CBI+HBI)
Number of subjects: 325

Group type: EXPERIMENTAL
Intervention: Control
Number of subjects: 325
Study: 36945034

Group type: EXPERIMENTAL
Intervention: CytoSorb hemoperfusion
Number of subjects: 24

Group type: COMPARATOR
Intervention: No intervention (control group)
Number of subjects: 24
Study: 36945037

Group type: EXPERIMENTAL
Intervention: High serum levels of IL-8
Number of subjects: 136

Group type: EXPERIMENTAL
Intervention: High serum levels of IL-10
Number of subjects: 136

Group type: EXPERIMENTAL
Intervention: High serum levels of CAIX
Number of subjects: 136

Group type: EXPERIMENTAL
Intervention: High serum levels of ADA
Number of subjects: 136

Group type: EXPERIMENTAL
Intervention: High serum levels of CASP8
Number of subjects: 136

Group type: EXPERIMENTAL
Intervention: High serum levels of FasL
Number of subjects: 136

Group type: EXPERIMENTAL
Intervention: CSF-1
Number of subjects: 136

Group type: EXPERIMENTAL
Intervention: IL-6
Number of subjects: 136

Group type: EXPERIMENTAL
Intervention: MUC16
Number of subjects: 136

Group type: EXPERIMENTAL
Intervention: TFNSFR4
Number of subjects: 136

Group type: EXPERIMENTAL
Intervention: CD244
Number of subjects: 136
Study: 36945146

Group type: EXPERIMENTAL
Intervention: Fully digital continuous self-screening for AF using a patch ECG device (ECG247 Smart Heart Sensor)
Number of subjects: 2118
Study: 36945200

Group type: EXPERIMENTAL
Intervention: ROTEM platelet aggregation using ARATEM
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: ROTEM platelet aggregation using ADPTEM
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: ROTEM platelet aggregation using TRAPTEM
Number of subjects: 40

Group type: COMPARATOR
Intervention: Comparison with Danish population
Number of subjects: 40
Study: 36945217

Group type: EXPERIMENTAL
Intervention: Drug-responsive phenomic alteration-related driver genes (PARGs) identified in the XYZ phenome
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Driver genes detected
Number of subjects: 0
Study: 36945475

Group type: EXPERIMENTAL
Intervention: Reduced lipid emulsion dosing
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual lipid emulsion dosing
Number of subjects: 0
Study: 36945495

Group type: EXPERIMENTAL
Intervention: Standard of care intravenous cytotoxic chemotherapy
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Patient-centered health data aggregating platform
Number of subjects: 200
Study: 36945579

Group type: EXPERIMENTAL
Intervention: Canagliflozin (300 mg)
Number of subjects: 30
Study: 36945773

Group type: EXPERIMENTAL
Intervention: Dual CAR T cells targeting CD19 and CD22 (obe-cel)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Single CAR targeting CD19
Number of subjects: 0

Group type: COMPARATOR
Intervention: Single CAR targeting CD22
Number of subjects: 0
Study: 36945823

Group type: EXPERIMENTAL
Intervention: Gaze-contingent music reward therapy (GC-MRT)
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Selective serotonin reuptake inhibitor (SSRI)
Number of subjects: 105

Group type: COMPARATOR
Intervention: Waiting list control
Number of subjects: 105
Study: 36945997

Group type: EXPERIMENTAL
Intervention: Topical lavender oil
Number of subjects: 180

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 180

Group type: COMPARATOR
Intervention: Control
Number of subjects: 180
Study: 36946138

Group type: EXPERIMENTAL
Intervention: Filgotinib 200 mg
Number of subjects: 0